CHRS · Forms 3, 4, 5
Insider trades at Coherus Oncology, Inc.
No open-market insider buys or sells at Coherus Oncology, Inc. in the last 90 days; 10 filings reported awards, option exercises, tax withholding or new insiders.
Every Form 3, 4 and 5 filed for Coherus Oncology, Inc. (CHRS) with the SEC, newest first: who traded, their role, buy or sell, shares, price and value.
Most recent insider filings
No Form 3, 4 or 5 filings for Coherus Oncology, Inc. in the last 90 days. The latest ones on EDGAR:
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Ali J. Satvat | Director | Award | 30,000 | Form 4 | |||
| Rita A Karachun | Director | Award | 30,000 | Form 4 | |||
| Lee Nisley Newcomer | Director | Award | 30,000 | Form 4 | |||
| Michael Lee Ryan | Director | Award | 30,000 | Form 4 | |||
| Jill O'Donnell-Tormey | Director | Award | 30,000 | Form 4 | |||
| Mats Wahlstrom | Director | Award | 30,000 | Form 4 | |||
| Charles W. Newton | Director | Award | 30,000 | Form 4 | |||
| Bryan J McMichael | Chief Financial Officer | Options or other derivatives | Form 4 | ||||
| Dennis M Lanfear | President & CEO | Options or other derivatives | Form 4 | ||||
| Dennis M Lanfear | President & CEO | Award | 375,000 | Form 4 |
Buy and Sell are open-market purchases and sales (transaction codes P and S), the trades investors watch. Awards, option exercises, tax withholding and gifts are reported too but are not market trades.